Antibody-drug conjugates (ADCs) are medications specifically designed to deliver chemotherapy to cancer cells. They consist of a cytotoxic drug linked to a monoclonal antibody, which binds to a specific target expressed on cancer cells. Upon binding to the target, the ADC releases a cytotoxic chemical into the cancer cell, aiming to destroy it.
The main components of antibody-drug conjugates include monoclonal antibodies, linkers, drugs or toxins, and others. Monoclonal antibodies are generated by cloning a single white blood cell, and each subsequent antibody is derived from a single parent cell. Some examples of ADC products include Adcetris, Kadcyla, and others. Various technologies, such as immunogen technology, Seattle Genetics technology, immunomedics technology, among others, are involved in the development of antibody-drug conjugates. These therapies find applications in treating conditions such as blood cancer, breast cancer, ovarian cancer, lung cancer, brain tumors, and others, and are implemented in hospitals, clinics, and other healthcare settings.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment-many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.
The antibody-drug conjugates (ADCs) market research report is one of a series of new reports from The Business Research Company that provides antibody-drug conjugates (ADCs) market statistics, including antibody-drug conjugates (ADCs) industry global market size, regional shares, competitors with an antibody-drug conjugates (ADCs) market share, detailed antibody-drug conjugates (ADCs) market segments, market trends and opportunities, and any further data you may need to thrive in the antibody-drug conjugates (ADCs) industry. This antibody-drug conjugates (ADCs) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The antibody drug conjugates market size has grown exponentially in recent years. It will grow from $13.57 billion in 2024 to $16.53 billion in 2025 at a compound annual growth rate (CAGR) of 21.8%. The growth in the historic period can be attributed to increasing prevalence of cancer, clinical success and approvals, strategic collaborations, growing investment in R&D, market expansion strategies.
The antibody drug conjugates market size is expected to see exponential growth in the next few years. It will grow to $37.9 billion in 2029 at a compound annual growth rate (CAGR) of 23.1%. The growth in the forecast period can be attributed to next generation ADCS, expanding indications, increasing focus on personalized medicine, rising investment in precision medicine, increasing healthcare awareness. Major trends in the forecast period include advancements in conjugation technologies, improved understanding of tumor biology, technological advancements, expanding therapeutic application, advanced conjugation technologies.
The forecast of 23.1% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. oncology centers by inflating prices of next-generation antibody-drug conjugate such as Enhertu and Trodelvy produced in Japan and Ireland, resulting in delayed targeted cancer therapy access and higher precision medicine treatment costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The global antibody-drug conjugates market is witnessing significant growth driven by the increasing incidence of cancer worldwide. Primary causes of most cancers, including obesity, smoking, alcohol consumption, and poor dietary habits, contribute to a rising trend. Cancer Research UK projects a substantial increase, estimating 27.5 million new cancer cases annually by 2040. This surge in cancer incidences is expected to boost the demand for antibody-drug conjugates, thereby propelling market growth.
The upward trajectory of the antibody-drug conjugates market is further fueled by a growing number of clinical trial studies. Clinical trials, essential for testing new treatments and interventions, play a crucial role in disease management. Antibody-drug conjugates, as a significant category of anti-cancer medications, are undergoing numerous clinical trials for treating blood-related cancers and solid tumors. Notably, there has been a substantial increase in registered clinical trials worldwide, with 452,604 listed on ClinicalTrials.gov, as reported by The Xtalks in May 2023. This uptrend indicates the rising prominence of clinical studies, contributing to the expansion of the antibody-drug conjugates market.
Manufacturers of antibody-drug conjugates are subject to monitoring by regulatory bodies, such as the Food and Drug Administration (FDA) in the USA. Although there is no specific regulatory guidance for ADC development, the FDA follows existing guidelines for small drugs and monoclonal antibodies to regulate ADC. Regulatory oversight focuses on aspects such as the manufacturing of the antibody component, control strategy for antibody intermediate, drug substance, and drug product. Small molecule review groups at the FDA play a key role in evaluating payload and linker adequacy, conjugation reactions, and aspects of the control strategy.
Manufacturers are increasingly engaging in collaborations and partnerships to share technology, resources, and product knowledge. An example is the collaboration between Sanofi, a French multinational pharmaceutical company, and Seagen Inc., a US biotechnology company, announced in March 2022. This collaboration aims to develop and market up to three cancer targets for antibody-drug conjugates, leveraging Sanofi's exclusive monoclonal antibody technology and Seagen's exclusive ADC technology. Such collaborations enhance synergies, fostering the creation of candidate medications to offer new hope to cancer patients.
Leading companies in the antibody-drug conjugates (ADCs) market are introducing groundbreaking conjugates, including the first single-use reactor specifically designed for ADC manufacturing. This innovative single-use reactor facilitates faster, more flexible, and contamination-free production of targeted cancer therapies by eliminating the need for cleaning and sterilization between batches. For example, in September 2024, Merck & Co., Inc., a US-based pharmaceutical company, launched the Mobius ADC reactor. This cutting-edge reactor addresses the growing demand for more efficient and safer manufacturing processes for ADCs, achieving a 70% increase in efficiency while significantly reducing the risks of cross-contamination and the labor-intensive cleaning associated with traditional stainless steel or glass reactors. The Mobius ADC Reactor utilizes Ultimus Film technology, which enhances bag strength, durability, and leak resistance, ensuring superior product quality.
Major companies operating in the antibody drug conjugates market include Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Millennium Pharmaceuticals Inc., Gilead Sciences Inc., Daiichi Sankyo Company Limited, Sorrento Therapeutics Inc., Astellas Pharma Inc., Zydus Lifesciences Limited, Seagen Inc., Seagen Inc., Synthon BV, Genentech Inc., ImmunoGen Inc., Nordic Nanovector ASA, ADC Therapeutics SA, Immunomedics Inc., Mersana Therapeutics Inc., Heidelberg Pharma AG, Celldex Therapeutics Inc., Oxford BioTherapeutics, Concortis Biotherapeutics Corp., Antikor BioPharma Ltd., Eisai Co. Ltd., Merck KGaA
North America was the largest region in the antibody-drug conjugates (ADCs) market in 2024. The Middle East is expected to be the fastest-growing region in the global antibody drug conjugates market share during the forecast period. The regions covered in the antibody drug conjugates market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the antibody drug conjugates market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The antibody-drug conjugates (ADCs) market consists of sales of enfortumab vedotin, sacituzumab govitecan, trastuzumab emtansine, and trastuzumab deruxtecan. Values in this market are factory gate values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Antibody Drug Conjugates Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on antibody drug conjugates market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for antibody drug conjugates ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The antibody drug conjugates market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Type: Monoclonal Antibodies; Linker; Drug/Toxin; Other Types
- 2) By Product: Adcertis; Kadcyla; Other Products
- 3) By Technology: Immunogen Technology; Seattle Genetics Technology; Immunomedics Technology; Other Technology
- 4) By Application: Blood Cancer; Breast Cancer; Ovarian Cancer; Lung Cancer; Brain Tumor; Other Applications
- 5) By End User: Hospital; Clinics; Other End Users
- Subsegments:
- 1) By Monoclonal Antibodies: IgG-based Monoclonal Antibodies; IgM-based Monoclonal Antibodies; Bispecific Antibodies
- 2) By Linker: Cleavable Linkers; Non-cleavable Linkers; Stable Linkers
- 3) By Drug/Toxin: Cytotoxic Drugs; Chemotherapeutic Agents; Radioisotopes
- 4) By Other Types: Enzyme-Targeted ADCs; Antibody-Drug Conjugates with Immune Modulators
- Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; AbbVie Inc.; AstraZeneca plc; Takeda Pharmaceutical Company Limited; Millennium Pharmaceuticals Inc.; Gilead Sciences Inc.; Daiichi Sankyo Company Limited; Sorrento Therapeutics Inc.; Astellas Pharma Inc.; Zydus Lifesciences Limited; Seagen Inc.; Seagen Inc.; Synthon BV; Genentech Inc.; ImmunoGen Inc.; Nordic Nanovector ASA; ADC Therapeutics SA; Immunomedics Inc.; Mersana Therapeutics Inc.; Heidelberg Pharma AG; Celldex Therapeutics Inc.; Oxford BioTherapeutics; Concortis Biotherapeutics Corp.; Antikor BioPharma Ltd.; Eisai Co. Ltd.; Merck KGaA
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time Series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Antibody Drug Conjugates Market Characteristics
3. Antibody Drug Conjugates Market Trends And Strategies
4. Antibody Drug Conjugates Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
- 4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Antibody Drug Conjugates Growth Analysis And Strategic Analysis Framework
- 5.1. Global Antibody Drug Conjugates PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Antibody Drug Conjugates Market Growth Rate Analysis
- 5.4. Global Antibody Drug Conjugates Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Antibody Drug Conjugates Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Antibody Drug Conjugates Total Addressable Market (TAM)
6. Antibody Drug Conjugates Market Segmentation
- 6.1. Global Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Monoclonal Antibodies
- Linker
- Drug/Toxin
- Other Types
- 6.2. Global Antibody Drug Conjugates Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Adcertis
- Kadcyla
- Other Products
- 6.3. Global Antibody Drug Conjugates Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Immunogen Technology
- Seattle Genetics Technology
- Immunomedics Technology
- Other Technology
- 6.4. Global Antibody Drug Conjugates Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Blood Cancer
- Breast Cancer
- Ovarian Cancer
- Lung Cancer
- Brain Tumor
- Other Applications
- 6.5. Global Antibody Drug Conjugates Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospital
- Clinics
- Other End Users
- 6.6. Global Antibody Drug Conjugates Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- IgG-based Monoclonal Antibodies
- IgM-based Monoclonal Antibodies
- Bispecific Antibodies
- 6.7. Global Antibody Drug Conjugates Market, Sub-Segmentation Of Linker, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Cleavable Linkers
- Non-cleavable Linkers
- Stable Linkers
- 6.8. Global Antibody Drug Conjugates Market, Sub-Segmentation Of Drug/Toxin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Cytotoxic Drugs
- Chemotherapeutic Agents
- Radioisotopes
- 6.9. Global Antibody Drug Conjugates Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Enzyme-Targeted ADCs
- Antibody-Drug Conjugates with Immune Modulators
7. Antibody Drug Conjugates Market Regional And Country Analysis
- 7.1. Global Antibody Drug Conjugates Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Antibody Drug Conjugates Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Antibody Drug Conjugates Market
- 8.1. Asia-Pacific Antibody Drug Conjugates Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Antibody Drug Conjugates Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Antibody Drug Conjugates Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Antibody Drug Conjugates Market
- 9.1. China Antibody Drug Conjugates Market Overview
- 9.2. China Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Antibody Drug Conjugates Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Antibody Drug Conjugates Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Antibody Drug Conjugates Market
- 10.1. India Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Antibody Drug Conjugates Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Antibody Drug Conjugates Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Antibody Drug Conjugates Market
- 11.1. Japan Antibody Drug Conjugates Market Overview
- 11.2. Japan Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Antibody Drug Conjugates Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Antibody Drug Conjugates Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Antibody Drug Conjugates Market
- 12.1. Australia Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Antibody Drug Conjugates Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Antibody Drug Conjugates Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Antibody Drug Conjugates Market
- 13.1. Indonesia Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Antibody Drug Conjugates Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Antibody Drug Conjugates Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Antibody Drug Conjugates Market
- 14.1. South Korea Antibody Drug Conjugates Market Overview
- 14.2. South Korea Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Antibody Drug Conjugates Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Antibody Drug Conjugates Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Antibody Drug Conjugates Market
- 15.1. Western Europe Antibody Drug Conjugates Market Overview
- 15.2. Western Europe Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Antibody Drug Conjugates Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Antibody Drug Conjugates Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Antibody Drug Conjugates Market
- 16.1. UK Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Antibody Drug Conjugates Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Antibody Drug Conjugates Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Antibody Drug Conjugates Market
- 17.1. Germany Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Antibody Drug Conjugates Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Antibody Drug Conjugates Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Antibody Drug Conjugates Market
- 18.1. France Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Antibody Drug Conjugates Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Antibody Drug Conjugates Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Antibody Drug Conjugates Market
- 19.1. Italy Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Antibody Drug Conjugates Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Antibody Drug Conjugates Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Antibody Drug Conjugates Market
- 20.1. Spain Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Antibody Drug Conjugates Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Antibody Drug Conjugates Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Antibody Drug Conjugates Market
- 21.1. Eastern Europe Antibody Drug Conjugates Market Overview
- 21.2. Eastern Europe Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Antibody Drug Conjugates Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Antibody Drug Conjugates Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Antibody Drug Conjugates Market
- 22.1. Russia Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Antibody Drug Conjugates Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Antibody Drug Conjugates Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Antibody Drug Conjugates Market
- 23.1. North America Antibody Drug Conjugates Market Overview
- 23.2. North America Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Antibody Drug Conjugates Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Antibody Drug Conjugates Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Antibody Drug Conjugates Market
- 24.1. USA Antibody Drug Conjugates Market Overview
- 24.2. USA Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Antibody Drug Conjugates Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Antibody Drug Conjugates Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Antibody Drug Conjugates Market
- 25.1. Canada Antibody Drug Conjugates Market Overview
- 25.2. Canada Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Antibody Drug Conjugates Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Antibody Drug Conjugates Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Antibody Drug Conjugates Market
- 26.1. South America Antibody Drug Conjugates Market Overview
- 26.2. South America Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Antibody Drug Conjugates Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Antibody Drug Conjugates Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Antibody Drug Conjugates Market
- 27.1. Brazil Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Antibody Drug Conjugates Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Antibody Drug Conjugates Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Antibody Drug Conjugates Market
- 28.1. Middle East Antibody Drug Conjugates Market Overview
- 28.2. Middle East Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Antibody Drug Conjugates Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Antibody Drug Conjugates Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Antibody Drug Conjugates Market
- 29.1. Africa Antibody Drug Conjugates Market Overview
- 29.2. Africa Antibody Drug Conjugates Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Antibody Drug Conjugates Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Antibody Drug Conjugates Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Antibody Drug Conjugates Market Competitive Landscape And Company Profiles
- 30.1. Antibody Drug Conjugates Market Competitive Landscape
- 30.2. Antibody Drug Conjugates Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
31. Antibody Drug Conjugates Market Other Major And Innovative Companies
- 31.1. Millennium Pharmaceuticals Inc.
- 31.2. Gilead Sciences Inc.
- 31.3. Daiichi Sankyo Company Limited
- 31.4. Sorrento Therapeutics Inc.
- 31.5. Astellas Pharma Inc.
- 31.6. Zydus Lifesciences Limited
- 31.7. Seagen Inc.
- 31.8. Seagen Inc.
- 31.9. Synthon BV
- 31.10. Genentech Inc.
- 31.11. ImmunoGen Inc.
- 31.12. Nordic Nanovector ASA
- 31.13. ADC Therapeutics SA
- 31.14. Immunomedics Inc.
- 31.15. Mersana Therapeutics Inc.
32. Global Antibody Drug Conjugates Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Antibody Drug Conjugates Market
34. Recent Developments In The Antibody Drug Conjugates Market
35. Antibody Drug Conjugates Market High Potential Countries, Segments and Strategies
- 35.1 Antibody Drug Conjugates Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Antibody Drug Conjugates Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Antibody Drug Conjugates Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
